ClinicalTrials.gg
CompletedNCT05214794Updated Feb 13, 2026Results posted

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

A Phase 2 interventional study of nemolizumab in Systemic Sclerosis, sponsored by Maruho Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Maruho Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Scleroderma, Systemic with a site in Japan — 4 open to participants now, 6 under way, 6 of them phase 3. Scleroderma, Systemic · Japan.

Enrollment
18th of 18
6 · median 111
Started
2022
with 3 others
Phase 2
6 of 18
none open now
Registered
11th of 18
by date

Among the 18 studies in Scleroderma, Systemic with a site in Japan, this one is the 18th largest by enrollment, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 11th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

4 of the 18 studies in Scleroderma, Systemic with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Scleroderma, Systemic with a site in Japan, or all of them as a file.
02

Study summary

To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.

03

Conditions studied

  • Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Systemic Sclerosis according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 criteria
  • Systemic Sclerosis patients with moderate to sever skin sclerosis

Exclusion criteria

Exclusion Criteria:

  • Patients witg a disease considered inappropriate for participation in clinical trials, such as serious cardiac / hepatic / renal / pulmonary / hematologic disease
  • Patients with a diseases that could interfere with assessment of Systemic Sclerosis
  • Patients with body weight less than 30.0kg
  • Pregnant or lactating women.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    nemolizumab

    Drug: nemolizumab

Interventions

  • nemolizumab will be administered subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24

    Compare pre- and post-treatment total mRSS at Week 24. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site

    Time frame: Baseline and week 24

Secondary outcomes

  1. Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52

    Compare pre- and post-treatment total mRSS at Week 52. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site

    Time frame: From baseline up to Week 52

  2. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24

    Compare pre- and post-treatment HAQ-DI at Week 24. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.

    Time frame: From baseline up to Week 24

  3. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52

    Compare pre- and post-treatment HAQ-DI at Week 52. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.

    Time frame: From baseline up to Week 52

  4. Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24

    Compare pre- and post-treatment %FVC at Week 24. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).

    Time frame: From baseline up to Week 24

  5. Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52

    Compare pre- and post-treatment %FVC at Week 52. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).

    Time frame: From baseline up to Week 52

  6. Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24

    Compare pre- and post-treatment %DLco at Week 24. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)

    Time frame: From baseline up to Week 24

  7. Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52

    Compare pre- and post-treatment %DLco at Week 52. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)

    Time frame: From baseline up to Week 52

  8. Change From Baseline in Physician's Global Assessment at Week 24

    Compare pre- and post-treatment physician's global assessment at Week 24. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.

    Time frame: From baseline up to Week 24

  9. Change From Baseline in Physician's Global Assessment at Week 52

    Compare pre- and post-treatment physician's global assessment at Week 52. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.

    Time frame: From baseline up to Week 52

  10. Change From Baseline in Patient's Global Assessment at Week 24

    Compare pre- and post-treatment patient's global assessment at Week 24. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.

    Time frame: From baseline up to Week 24

  11. Change From Baseline in Patient's Global Assessment at Week 52

    Compare pre- and post-treatment patient's global assessment at Week 52. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.

    Time frame: From baseline up to Week 52

07

Results

Posted Feb 13, 2026

Participant flow

The study was conducted at one site in Japan from April 2022 to July 2024

Participant flow — Overall Study
MilestoneNemolizumab
Started6
Completed6
Not completed0

Outcome measures

PrimaryChange From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24

Compare pre- and post-treatment total mRSS at Week 24. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site

Time frame:
Baseline and week 24
Reported as:
Median · scores on scale
Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24
scores on scaleNemolizumab
Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24-9.5 (-13 to -6)
SecondaryChange From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52

Compare pre- and post-treatment total mRSS at Week 52. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site

Time frame:
From baseline up to Week 52
Reported as:
Median · scores on scale
Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52
scores on scaleNemolizumab
Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52-10.0 (-14 to -7)
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24

Compare pre- and post-treatment HAQ-DI at Week 24. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.

Time frame:
From baseline up to Week 24
Reported as:
Median · scores on scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
scores on scaleNemolizumab
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 240.000 (-0.13 to 0.38)
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52

Compare pre- and post-treatment HAQ-DI at Week 52. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.

Time frame:
From baseline up to Week 52
Reported as:
Median · scores on scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52
scores on scaleNemolizumab
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 520.063 (-0.13 to 0.25)
SecondaryChange From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24

Compare pre- and post-treatment %FVC at Week 24. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).

Time frame:
From baseline up to Week 24
Reported as:
Median · percentage of actual to predicted FCV
Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24
percentage of actual to predicted FCVNemolizumab
Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24-1.30 (-3.5 to 5.7)
SecondaryChange From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52

Compare pre- and post-treatment %FVC at Week 52. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).

Time frame:
From baseline up to Week 52
Reported as:
Median · percentage of actual to predicted FCV
Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52
percentage of actual to predicted FCVNemolizumab
Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52-0.35 (-6.4 to 5.7)
SecondaryChange From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24

Compare pre- and post-treatment %DLco at Week 24. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)

Time frame:
From baseline up to Week 24
Reported as:
Median · percentage of actual to predicted DLco
Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24
percentage of actual to predicted DLcoNemolizumab
Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 240.55 (-4.5 to 8.8)
SecondaryChange From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52

Compare pre- and post-treatment %DLco at Week 52. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)

Time frame:
From baseline up to Week 52
Reported as:
Median · percentage of actual to predicted DLco
Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52
percentage of actual to predicted DLcoNemolizumab
Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52-3 (-6.6 to 4.4)
SecondaryChange From Baseline in Physician's Global Assessment at Week 24

Compare pre- and post-treatment physician's global assessment at Week 24. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.

Time frame:
From baseline up to Week 24
Reported as:
Median · scores on scale
Change From Baseline in Physician's Global Assessment at Week 24
scores on scaleNemolizumab
Change From Baseline in Physician's Global Assessment at Week 24-3.30 (-5.4 to -0.9)
SecondaryChange From Baseline in Physician's Global Assessment at Week 52

Compare pre- and post-treatment physician's global assessment at Week 52. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.

Time frame:
From baseline up to Week 52
Reported as:
Median · scores on scale
Change From Baseline in Physician's Global Assessment at Week 52
scores on scaleNemolizumab
Change From Baseline in Physician's Global Assessment at Week 52-3.10 (-6.5 to -0.6)
SecondaryChange From Baseline in Patient's Global Assessment at Week 24

Compare pre- and post-treatment patient's global assessment at Week 24. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.

Time frame:
From baseline up to Week 24
Reported as:
Median · scores on scale
Change From Baseline in Patient's Global Assessment at Week 24
scores on scaleNemolizumab
Change From Baseline in Patient's Global Assessment at Week 241.30 (-1.8 to 3.8)
SecondaryChange From Baseline in Patient's Global Assessment at Week 52

Compare pre- and post-treatment patient's global assessment at Week 52. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.

Time frame:
From baseline up to Week 52
Reported as:
Median · scores on scale
Change From Baseline in Patient's Global Assessment at Week 52
scores on scaleNemolizumab
Change From Baseline in Patient's Global Assessment at Week 521.70 (-0.1 to 5.1)

Adverse events

Collected over From baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nemolizumab0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventNemolizumab
NasopharyngitisInfections and infestations3/6
Adenoviral conjunctivitisInfections and infestations1/6
GastroenteritisInfections and infestations1/6
ParonychiaInfections and infestations1/6
Tinea pedisInfections and infestations1/6
Oral herpesInfections and infestations1/6
COVID-19Infections and infestations1/6
Animal biteInjury, poisoning and procedural complications1/6
Ligament sprainInjury, poisoning and procedural complications1/6
Vaccination complicationInjury, poisoning and procedural complications1/6

Baseline characteristics

FAS population included all participants who were enrolled.

Age, Categorical
Age, Categorical(Participants)Nemolizumab
<=18 years0
Between 18 and 65 years5
>=65 years1
Age, Continuous
Age, Continuous(year)Nemolizumab
Median53.5 (50 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Nemolizumab
Female6
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nemolizumab
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nemolizumab
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nemolizumab
Japan6
Classification of Primary Disease
Classification of Primary Disease(Participants)Nemolizumab
Diffuse Cutaneous SSc4
Limited Cutaneous SSc2
Modified Rodnan Total Skin Thickness Score (Total mRSS)
Modified Rodnan Total Skin Thickness Score (Total mRSS)(scores on scale)Nemolizumab
Median16 (12 to 22)

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • The University of Tokyo Hospital
    Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jun 2024, 25 months.

Results were first posted in Feb 2026, 1 year 8 months after primary completion.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Jan 31, 2022
StartActual
Apr 20, 2022
Primary completionActual
Jun 4, 2024
CompletionActual
Jul 30, 2024
Results first posted
Feb 13, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05214794
Lead sponsor
Maruho Co., Ltd.
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Apr 20, 2022
Primary completion
Jun 4, 2024
Completion
Jul 30, 2024
Results posted
Feb 13, 2026
Last update
Feb 13, 2026

Study contacts

Ayumi Yoshizaki, MD, PhD
principal investigator · Tokyo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion